louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04299204: The Success of Pediatric Percutaneous Nephrolithotomy
Official title: Which Factor Affect the Success of Pediatric PCNL?: Single Center Experiences, Over 20 Years: Cohort Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nephrolithiasis
Keywords: Urolithiasis
Pediatrics
Percutaneous
Lead sponsor: Osmaniye Government Hospital
Sponsor class: OTHER_GOV
First posted: 2020-03-06
Enrollment: 553
Sex: ALL
Minimum age (years): 1
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: the data into two groups. In group-1, PCNL was performed in the first 10 years period (1997-2007); in group-2, PCNL was performed in the second ten years period from 2008 to the present.
Primary purpose: TREATMENT

Brief summary: Between June 1997-June 2018, 573 pediatric patients underwent PCNL for renal stone disease by senior surgeons. Data was disunited into 2 groups.

The study showed that PCNL is an operator-dependent procedure, with the improvement of outcomes over time, presumably due to increased operator experience and the involvement of a team member with substantial prior experience During 20 years, by gaining experience and with the development of new tools and optics, fluoroscopy time, operation time, blood loss and complication rates decreased and stone-free rates increased.


Eligibility criteria: Inclusion Criteria:

* Pediatric patients with kidney stone

Exclusion Criteria:

* Patients with a solitary kidney

Primary outcomes:
measure: Safety and Efficacy of clinical experience of Percutaneous nephrolitotomy
timeFrame: over 20 years
Secondary outcomes:
measure: Changing of complications managements
timeFrame: Over 20 years
Other outcomes:
Locations:
Study officials:
References:
citation: Citamak B, Altan M, Bozaci AC, Koni A, Dogan HS, Bilen CY, Sahin A, Tekgul S. Percutaneous Nephrolithotomy in Children: 17 Years of Experience. J Urol. 2016 Apr;195(4 Pt 1):1082-7. doi: 10.1016/j.juro.2015.11.070. Epub 2015 Dec 9.
Clinical trial NCT03302104: Diet Quality and LTL in NHANES
Official title: Diet Quality Indices and Leukocyte Telomere Length Among Healthy US Adults: Data From the National Health and Nutrition Examination Surveys (NHANES) 1999-2002
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Telomere Length, Mean Leukocyte
Diet Habit
Lead sponsor: University of California, San Francisco
Sponsor class: OTHER
First posted: 2017-10-04
Enrollment: 4758
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: The study population was comprised of 4,758 healthy adults, aged 20 to 65 years, who had complete dietary and leukocyte telomere length (LTL) data measured in 1999-2002 National Health and Nutrition Examination Surveys (NHANES), without a prior diagnosis of major chronic disease (coronary heart disease, angina, myocardial infarction, stroke, diabetes, congestive heart failure, and cancer).

Brief summary: In our study, we used data from 4,758 healthy adults from the 1999-2002 National Health and Nutrition Examination Surveys to examine the associations between evidence-based diet quality indices and leukocyte telomere length. Our study assessed the four most widely recognized and commonly used diet quality indices in nutritional epidemiology: the USDA-developed Healthy Eating Index-2010, the Alternate Healthy Eating Index-2010, the Mediterranean Diet Score, and the DASH diet score. Analyses were adjusted for sociodemographic and health variables known to influence dietary intake and cellular aging.


Eligibility criteria: Inclusion Criteria:

* Ages 20 to 65 years
* No prior diagnosis of major chronic disease (coronary heart disease, angina, myocardial infarction, stroke, diabetes, congestive heart failure, and cancer)

Exclusion Criteria:

* Prior diagnosis of major chronic disease (coronary heart disease, angina, myocardial infarction, stroke, diabetes, congestive heart failure, and cancer)
* Younger than age 20 or older than age 65

Primary outcomes:
measure: Leukocyte telomere length
timeFrame: 1999-2002
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01717404: Effects of Mexiletine on Colonic Transit in a Patient With Irritable Bowel Syndrome - Constipation (IBS-C)
Official title: Effects of Mexiletine on Colonic Transit in a Patient With a Known SCN5A A997T Mutation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: IBS
Keywords: IBS
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2012-10-30
Enrollment: 1
Sex: FEMALE
Minimum age (years): 60
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To understand if Mexiletine will restores normal colonic motility in a patient with irritable bowel syndrome - constipation (IBS-C) and a genetic mutation in SCN5A.

Detailed description: To understand if Mexiletine will restore normal colonic motility in a patient with a missense mutation in SCN5A, which encodes a voltage-sensitive sodium channel NaV1.5 as it is known to rescue certain expression defects of NaV1.5 in vitro.

Eligibility criteria: Inclusion Criteria:

* Established IBS diagnosis with a known A997T mutation in NaV1.5T

Exclusion Criteria:

* Normal 48-hour baseline transit study
* Current use of mexiletine
* Inability to stay in Rochester for 9 days for testing
* Known allergy to mexiletine
* Inability to complete daily diary
* Taking a medication known to affect myotonia, had a coexisting neuromuscular disease, or had another serious medical illness including second- or third-degree heart block, atrial flutter, atrial fibrillation, ventricular arrhythmia, history of cardiac arrhythmia requiring medication, congestive heart failure, symptomatic cardiomyopathy, or symptomatic coronary artery disease
* Inability to withdraw medications known to interact with mexiletine. Patient is currently not on any of these medications

Primary outcomes:
measure: change in the 48 hour Colon Transit
timeFrame: Baseline to 10 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Mayo Clinic
name: Yuri A Saito Loftus, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
citation: Beyder A, Mazzone A, Strege PR, Tester DJ, Saito YA, Bernard CE, Enders FT, Ek WE, Schmidt PT, Dlugosz A, Lindberg G, Karling P, Ohlsson B, Gazouli M, Nardone G, Cuomo R, Usai-Satta P, Galeazzi F, Neri M, Portincasa P, Bellini M, Barbara G, Camilleri M, Locke GR, Talley NJ, D'Amato M, Ackerman MJ, Farrugia G. Loss-of-function of the voltage-gated sodium channel NaV1.5 (channelopathies) in patients with irritable bowel syndrome. Gastroenterology. 2014 Jun;146(7):1659-1668. doi: 10.1053/j.gastro.2014.02.054. Epub 2014 Mar 5.
Clinical trial NCT01564004: Clinical Hypnosis Before External Cephalic Version (ECV)
Official title: Clinical Hypnosis Versus Neuro-linguistic Programming Before External Cephalic Version (ECV) - a Prospective Off-centre Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Breech Presentation at Term
Keywords: breech presentation at term
pregnancy
external cephalic version (ECV)
clinical hypnosis
neuro-linguistic programming (NLP)
Lead sponsor: Johann Wolfgang Goethe University Hospital
Sponsor class: OTHER
First posted: 2012-03-27
Enrollment: 716
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Does clinical hypnosis or neuro-linguistic programming improve the success rate of external cephalic version?

Detailed description: Prospective off-center randomisation of clinical hypnosis or neuro-linguistic programming intervention prior to a external cephalic version treatment.

Eligibility criteria: Inclusion Criteria:

* singleton
* breech presentation
* gestation age above 36 weeks + 6 days

Exclusion Criteria:

* multiples
* cannot understand German language

Primary outcomes:
measure: Successful ECV
timeFrame: 3 hours after ECV treatment
Secondary outcomes:
measure: Questionnaire
timeFrame: before and 30 minutes after ECV
Other outcomes:
Locations:
city: Frankfurt
country: Germany
facility: Department of obstetrics and gynaecology, Johann Wolfgang Goethe University
state: Hessen
Study officials:
References:
Clinical trial NCT02848404: Therapeutic Efficacy of Categorical Language Fluency Smartphone Game Application
Official title: A Study of Therapeutic Efficacy of Categorical Language Fluency Smartphone Game Application in Mild Cognitive Impairment and Mild Alzheimer's Dementia (Baseline Study)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mild Cognitive Impairment
Alzheimer's Disease
Keywords: Mild cognitive impairment
Cognitive rehabilitation
Cognitive therapy
Alzheimer's disease
Memory enhancement
Categorical language fluency
Lead sponsor: Seoul National University Bundang Hospital
Sponsor class: OTHER
Collaborators: name: Seoul National University
name: Ministry of Science and ICT, Republic of Korea
First posted: 2016-07-28
Enrollment: 20
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to examine therapeutic efficacy of categorical language fluency smartphone game application in mild cognitive impairment and mild Alzheimer's dementia.

Detailed description: The Categorical Language Fluency Smartphone Game Application was developed based on the semantic distance training, which was effective in improving categorical language fluency of mild cognitive impairment and mild Alzheimer's dementia. 10 patients with mild cognitive impairment and another 10 patients with mild Alzheimer's dementia were recruited to examine therapeutic efficacy of the application.

Eligibility criteria: Inclusion Criteria:

* Aged above 55
* Confirmed literacy

  * Diagnosed to mild cognitive impairment by International Working Group on Mild Cognitive Impairment and Clinical Dementia Rating(CDR) of 0 or 0.5.
  * Diagnosed to possible or probable Alzheimer's dementia by NINCDS-ADRDA and Clinical Dementia Rating(CDR) of 1 or below.

Exclusion Criteria:

* Evidence of delirium, confusion
* Any neurological conditions causing cognitive decline such as Parkinson's disease, brain hemorrhage, brain tumor, normal pressure hydrocephalus
* Evidence of severe cerebrovascular pathology
* History of loss-of-consciousness over 1 hour due to head trauma or repetitive head trauma of mild severity
* History of substance abuse or dependence such as alcohol
* Presence of depressive symptoms that could influence cognitive function
* Presence of medical comorbidities that could result in cognitive decline

Primary outcomes:
measure: Application usage log
timeFrame: 4-weeks treatment
Secondary outcomes:
measure: Subjective Memory Complaint Questionnaire
timeFrame: after 4-weeks treatment
measure: Geriatric Depression Scale
timeFrame: after 4-weeks treatment
measure: Korean version of MMSE for dementia screening
timeFrame: after 4-weeks treatment
Other outcomes:
Locations:
Study officials:
affiliation: Seoul National University Bundang Hospital, Seong-nam, Korea
name: Ki Woong Kim, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03806504: High PEEP Application Following Pulmonary Thromboendarterectomy; Does it Have Any Impact on Outcome?
Official title: Prospective Randomized Trial of Impact of High PEEP Application Following Pulmonary Endarterectomy on Outcome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Reperfusion Injury After Pulmonary Thromboendarterektomy
Keywords: Chronic thromboembolic pulmonary hypertension
PEEP
reperfusion injury
Lead sponsor: Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital
Sponsor class: OTHER_GOV
First posted: 2019-01-16
Enrollment: 60
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: prospective, randomized
Primary purpose: PREVENTION

Brief summary: Investigation of the effect of intraoperative lung protection high PEEP maneuver on ischemic reperfusion injury in patients undergoing pulmonary endarterectomy.

Detailed description: Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare disease characterized by progression of thromboembolism obstructing pulmonary arteries as an organized tissue. Pulmonary thromboendarterectomy (PTE) is a treatment option for chronic thromboembolic pulmonary disease. However, PTE is associated with specific postoperative complications, such as pulmonary edema and right ventricular failure due to reperfusion injury, with a significant mortality rate of 7% to 24%. Some strategies have been proposed to reduce lung injury after PTE, such as rectification maneuvers and high PEEP. The aim of this study was to investigate the effect of intraoperative lung protection high PEEP maneuver in patients undergoing pulmonary endarterectomy for ischemic reperfusion injury.

Eligibility criteria: Inclusion Criteria:

* Patients undergoing elective PTE operation due to CTEPH,
* 20-70 years old

Exclusion Criteria:

* Patients with chronic inflammatory disease,
* liver and renal failure,
* heart failure (\<EF: 40%),
* intraoperative bronchial hemorrhage,
* patients undergoing postoperative revision.

Primary outcomes:
measure: free oxygen radicals levels
timeFrame: 48 hours
Secondary outcomes:
measure: postoperatif outcome - Duration of stay in the intensive care unit and hospital stay
timeFrame: 10 day
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Mustafa EMRE Gurcu
Study officials:
References:
Clinical trial NCT03796104: Prognostic Impact of Delta-haemolysin Production Deficiency in Staphylococcus Aureus on the Prognosis of Infected Implant Treated by DAIR
Official title: Prognostic Impact of Delta-haemolysin Production Deficiency in Staphylococcus Aureus on the Prognosis of Infected Implant Treated by DAIR
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Bone and Joint Infection
Staphylococcus Aureus
Keywords: Bone and Joint Infection
Staphylococcus Aureus
chronic infection
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2019-01-08
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: patients having implant infection due to S. aureus treated by DAIR managed at the Lyon Bone and joint infection reference Center between 2006 and 2018

Brief summary: The aim of this study is to determine if delta-haemolysin production deficiency of Staphylococcus aureus is a marker in favour of chronic infections on implants


Eligibility criteria: Inclusion Criteria:

* patients having implant infection due to S. aureus treated by DAIR

Exclusion Criteria:

* none

Primary outcomes:
measure: Rate of infection with or witout delta-haemolysin in Staphylococcus Aureus
timeFrame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Secondary outcomes:
measure: Rate of Treatment Failure
timeFrame: Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption
Other outcomes:
Locations:
city: Lyon
country: France
facility: Hospices Civils de Lyon
Study officials:
affiliation: Hospices Civils de Lyon
name: FLORENT VALOUR, Md,PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06995404: Transversus Abdominis Plane Block (TAP) Versus Thoracoabdominal Nerve Block Through Perichondrial Approach (M-TAPA) in Laparoscopic Gynecologic Surgeries
Official title: Transversus Abdominis Plane Block (TAP) Versus Thoracoabdominal Nerve Block Through Perichondrial Approach (M-TAPA) in Laparoscopic Gynecologic Surgeries
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Gynecologic Laparoscopic Surgery
Regional Anesthesia Block
Lead sponsor: Ankara Etlik City Hospital
Sponsor class: OTHER_GOV
First posted: 2025-05-29
Enrollment: 90
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Although laparoscopic techniques are considered minimally invasive surgical procedures with lower perioperative pain scores compared to open surgeries, they are still associated with significant levels of pain. This study aims to investigate the analgesic effectiveness of two routinely performed regional analgesic techniques in our clinic-ultrasound-guided classic bilateral TAP block and ultrasound-guided bilateral M-TAPA block-in patients undergoing laparoscopic gyneco-oncologic surgery (LGOS), as well as their effects on intraoperative opioid consumption.


Eligibility criteria: Inclusion Criteria:Female patients aged between 18 and 80 years, classified as ASA physical status I to III, undergoing laparoscopic gynecologic surgery under general anesthesia -

Exclusion Criteria:Coagulopathy

Neuropathy

Chronic analgesic therapy

Severe cardiopulmonary disease

Uncontrolled diabetes mellitus (HbA1c \> 8%)

Severe renal or hepatic failure

Pregnancy or lactation

Body mass index (BMI) greater than 35 kg/m²

Local infection at the injection site

Inability to comprehend pain scores or cooperate (e.g., Alzheimer's disease, mental retardation)

Allergy to local anesthetic agents

Refusal to participate in the study

-

Primary outcomes:
measure: Evaluation of intraoperative opioid consumption
timeFrame: during surgery
Secondary outcomes:
measure: Comparison of postoperative Visual Analog Scale (VAS) pain scores
timeFrame: postoperative first day
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Ankara Etlik City Hospital
Study officials:
References:
Clinical trial NCT06981104: Tear Film Stability and Improvement of Asthenopia: Efficacy Observation of 0.05% Cyclosporine in Dry Eye Patients With Short BUT
Official title: A Randomized, Double-blind, Controlled Clinical Study on the Efficacy and Safety of 0.05% Cyclosporine Eye Drops in the Treatment of Mild to Moderate Dry Eye
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dry Eye Disease (DED)
Asthenopia
Lead sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Sponsor class: OTHER
First posted: 2025-05-20
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: At present, research on cyclosporine mainly focuses on patients with moderate to severe dry eye. Based on the importance of the vicious cycle of inflammation in the pathogenesis of dry eye and the mechanism of cyclosporine, we believe that it may also have therapeutic effects in patients with mild to moderate dry eye, and may have certain advantages compared to traditional artificial tear therapy. In summary, this study intends to use a randomized, double-blind, parallel controlled trial to evaluate the therapeutic efficacy and safety of 0.05% cyclosporine eye drops in patients with mild to moderate dry eyes.


Eligibility criteria: Inclusion Criteria:

1. 18-75 years old (including 18 and 75 years old), male or female;
2. Meets the diagnostic criteria for dry eye syndrome in China (2020) and is mild dry eye 1) Dry Eye Questionnaire (OSDI) score ≥ 13 points; 2) BUT ≤ 10 seconds or Schirmer I ≤ 5mm/5 minutes 3) Corneal staining positive ≤ 5 points.
3. At least one of OSDI, BUT, and Schirmer I meets the moderate standard OSDI ≥ 23 points; BUT\<5 seconds; Schirmer I \< 5mm/5min
4. The subjects themselves signed an informed consent form and voluntarily participated in this study.

Exclusion Criteria:

1. Women who are breastfeeding or pregnant, or men and women of childbearing age who are unable to use effective contraceptive methods during the study period;
2. Those who need to wear contact lenses during treatment;
3. Acute inflammation, infection, allergy, and trauma of the eyes;
4. There are obvious scars or keratinization on the eyelid margin;
5. Have undergone eye or eyelid surgery within the 6 months prior to enrollment;
6. Diagnosed with facial nerve paralysis or ocular nerve paralysis within 6 months prior to enrollment;
7. Currently using lacrimal duct embolization (permanent lacrimal plug or treatment with lacrimal plug within 6 months);
8. I am currently taking medication that may affect dry eye syndrome.

Primary outcomes:
measure: Fluorescent tear film breakup time
timeFrame: 8weeks
measure: high-frequency component（HFC）
timeFrame: 8weeks
measure: visual fatigue index
timeFrame: 8weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Hangzhou
country: China
facility: 1 Xihu Avenue, Shangcheng District, Hangzhou, Zhejiang, China
state: Zhejiang
Study officials:
References:
Clinical trial NCT01924104: Effects of Aspirin and Low Molecular Weight Heparin in IVF Outcome.
Official title: Effects of Low Dose Aspirin and Low Molecular Weight Heparin Cotreatment, Alone and/or in Combination on Implantation and Clinical Pregnancy Rates in Repeated Implantation Failures in IVF Cycle.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: To Investigate the Effects of Low Dose Aspirin and Low Molecular Weight Heparin in IVF Out Come
Keywords: IVF failure, implantation rate, heparin & aspirin
Lead sponsor: Jeevan Jyoti Hospital
Sponsor class: OTHER
First posted: 2013-08-16
Enrollment: 400
Sex: FEMALE
Minimum age (years): 19
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to determine whether low-dose aspirin and low molecular weight heparin improve the implantation and pregnancy rates in patients with repeated implantation failures in IVF cycle.

Detailed description: The investigators hypothesize that cotreatment of low dose aspirin \& low molecular weight heparin may improve implantation \& clinical pregnancy rates.

Eligibility criteria: Inclusion Criteria:

* Aged between 19 to 35 years;
* Basal follicle-stimulating hormone (FSH) levels of ≤8 IU/l
* Body mass index (BMI) between 19 kg/m2 and 25 kg/m2
* Presence of both ovaries; ≥2 previous IVF failures
* Good quality embryos for transfer
* Endometrial thickness between 10 mm and 14 mm

Exclusion Criteria:

* Polycystic ovary syndrome
* Endometriosis

Primary outcomes:
measure: Biological pregnancy test
timeFrame: 14 days
Secondary outcomes:
measure: Fetal heart/Gestational sac
timeFrame: 8 weeks
Other outcomes:
Locations:
city: Allahabad
country: India
facility: Arpit Test Tube Baby Centre, Jeevan Jyoti Hospital & Research Centre
state: Uttar Pradesh
Study officials:
affiliation: Arpit Test Tube Baby Centre, Vandana Women's Hospital, Jeevan Jyoti Hospital & Research Centre
name: Vandana Bansal, MS DGO PhD
role: PRINCIPAL_INVESTIGATOR
References: